{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T07:32:28Z","timestamp":1773559948406,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,5,4]],"date-time":"2010-05-04T00:00:00Z","timestamp":1272931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> There is a lack of evidence for guiding the best strategy for ABO selection of platelet (PLT) transfusions. As a baseline for future studies, the BEST Collaborative performed an international survey of current practices in this area.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> An international survey was sent via BEST members to transfusion services and hospitals requesting the demographics of the transfused patient population, ABO matching policies, anti\u2010A and anti\u2010B measurements in PLT concentrates (PCs), and practices regarding ABO\u2010incompatible PC transfusions to adult and pediatric patients.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> We received 126 responses from 14 countries, 59% from Europe. Most of them were from local\/community (42%) and university hospitals (39%) serving between 500 and 1500 beds; 50.4% transfused fewer than 1000 PCs per year. One\u2010fifth of respondents (19.4%, mainly local\/community hospitals) did not have a written policy for selecting ABO\u2010incompatible PCs. Significant practice variation was reported when ABO\u2010mismatched PLTs were given to adults: for PCs suspended in 100% plasma, 29% to 43% of respondents selected any ABO group available; 52% to 61% selected units with compatible supernatant; and, in the case of minor ABO incompatibility, 43% to 54% did not take any specific action. In contrast if ABO\u2010identical PCs were not available for a pediatric recipient, for PCs resuspended in 100% plasma, 71% to 82% selected PCs so the supernatant plasma would be compatible with patient's red blood cells.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Considerable practice variation exists when transfusing ABO\u2010incompatible PCs, suggesting an opportunity for research to inform evidence\u2010based practices.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2010.02642.x","type":"journal-article","created":{"date-parts":[[2010,5,5]],"date-time":"2010-05-05T03:48:03Z","timestamp":1273031283000},"page":"1743-1748","source":"Crossref","is-referenced-by-count":31,"title":["Practices associated with ABO\u2010incompatible platelet transfusions: a BEST Collaborative international survey"],"prefix":"10.1111","volume":"50","author":[{"given":"Miguel","family":"Lozano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Heddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna M","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"AuBuchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,2]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"KleinE DjerassiI FarberS.Maintenance of normal platelet levels in recipients of multiple transfusions of platelets from incompatible blood. Proceedings of the VIIth Congress of the International Society of Hematology. Rome Sept. 7\u201013. 957 1958."},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196301312680501"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V65.3.615.615"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a121845"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-0038-1647483","article-title":"Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib","volume":"65","author":"Santoso S","year":"1991","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28588337336.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.3.993.993"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1574"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb02873.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3080"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00526.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01455.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V26.6.732.732"},{"key":"e_1_2_8_15_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood.V54.3.595.595","article-title":"ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients","volume":"54","author":"Duguesnoy RJ","year":"1979","journal-title":"Blood"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.1.23.23"},{"key":"e_1_2_8_17_2","first-page":"1035","article-title":"Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation","volume":"17","author":"Klumpp TR","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01914.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695973"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb04356.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03349.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830450219"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111273.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41060790.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000167758.63247.f4"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01167.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/tmrv.2003.50003"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-909-TOPCAP"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04468.x"},{"key":"e_1_2_8_30_2","volume-title":"Standards for blood banks and transfusion services","author":"Gorlin JB","year":"2002"},{"key":"e_1_2_8_31_2","first-page":"218","article-title":"International Forum. Transfusion of apheresis platelets and ABO groups","volume":"88","author":"Maclennan S","year":"2005","journal-title":"Vox Sang"},{"key":"e_1_2_8_32_2","unstructured":"Serious Hazards of Transfusion Steering Committee.Serious hazards of transfusion: annual report 2008. Manchester (UK):SHOT Office;2009[cited 2010 Mar 12]. Available from: URL:http:\/\/www.shotuk.org\/SHOT%20Report%202008.pdf"},{"key":"e_1_2_8_33_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21307\/immunohematology-2019-314","article-title":"ABO and platelet transfusion therapy","volume":"23","author":"Cooling L","year":"2007","journal-title":"Immunohematology"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139880002300908"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2010.02642.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2010.02642.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:45:39Z","timestamp":1697283939000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2010.02642.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1537-2995.2010.02642.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2010.02642.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}